Latest News - Zimmer Biomet
Top Corporates Hub
Zimmer Biomet
3 Reasons to Avoid ZBH and 1 Stock to Buy Instead
20.02.2026 04:04
Over the past six months, Zimmer Biomet’s stock price fell to $99.27. Shareholders have lost 6.1% of their capital, which is disappointing considering the S&P 500 has climbed by 7.6%. This might have investors contemplating their next move.
Zimmer Biomet Holdings Inc (ZBH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...
12.02.2026 01:04
Zimmer Biomet Holdings Inc (ZBH) reports robust Q4 2025 performance with a 5.4% organic revenue growth and outlines plans for a dedicated US sales channel by 2027.
Zimmer Biomet Q4 Earnings Call Highlights
11.02.2026 07:07
Zimmer Biomet (NYSE:ZBH) reported fourth-quarter 2025 results that management said met its commitments on sales growth, earnings, and free cash flow despite tariff headwinds and the integration of three acquisitions during the year. Executives also outlined a major ongoing shift in the company’s U.S
Zimmer Biomet reports 2025 revenue growth yet tempers 2026 outlook
10.02.2026 17:55
Zimmer’s CEO said its 2026 outlook remains cautious as it focuses on product adoption, a US salesforce transition, and international market performance.
ZBH Q4 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
10.02.2026 16:11
Zimmer Biomet beats Q4 earnings and revenue estimates, with sales up 10.9% and shares rising 1.4% pre-market despite margin contraction.
Zimmer Biomet (ZBH) Q4 2025 Earnings Transcript
10.02.2026 15:07
Ivan Tornos: Good morning, everyone, and thank you for joining today's call. Today, Zimmer Biomet is a totally different company than it was just a few short years ago, and this is no doubt due to your efforts. Starting with the year and the fourth quarter, I'm proud of how the team ended the year 2025, delivering on our commitments on sales growth, EPS, and free cash flow while navigating quite a complex challenge in the year.
Zimmer (ZBH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10.02.2026 14:30
The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zimmer Biomet beats quarterly estimates on strong hips, knees device demand
10.02.2026 13:19
Feb 10 () - Zimmer Biomet on Tuesday beat Wall Street estimates for fourth-quarter profit and revenue as the company capitalized on steady demand for its devices used in orthopedic procedures. Shares of the Warsaw, Indiana based company rose 1.
Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates
10.02.2026 12:40
Zimmer (ZBH) delivered earnings and revenue surprises of +1.70% and +1.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zimmer Biomet (NYSE:ZBH) Beats Q4 CY2025 Sales Expectations
10.02.2026 11:45
Medical device company Zimmer Biomet (NYSE:ZBH) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 10.9% year on year to $2.24 billion. Its non-GAAP profit of $2.42 per share was 0.9% above analysts’ consensus estimates.
Zimmer: Q4 Earnings Snapshot
10.02.2026 11:36
The Warsaw, Indiana-based company said it had net income of 70 cents per share. Earnings, adjusted for amortization costs and non-recurring costs, came to $2.42 per share. The results beat Wall Street expectations.
Zimmer Biomet Announces Fourth Quarter and Full-Year 2025 Financial Results
10.02.2026 11:30
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2025. The Company reported fourth quarter net sales of $2.244 billion, an increase of 10.9% over the prior year period, an increase of 9.2% on a constant currency1 basis and an increase of 5.4% on an organic constant currency1 basis. Net sales for the full year were $8.232 billion, an increase of 7.2% over the prior year, an increase of 6.4% on a constant currency1 basis
Tissue and Regenerative Engineering Market Company, Government & Public Sector Funding Data
10.02.2026 10:01
Precedence Research, a leading strategic research firm, presents an in-depth analysis of the Tissue and Regenerative Engineering market, highlighting key company performance, product focus, and government funding initiatives. Tissue engineering and regenerative biomaterials are advancing rapidly, with innovations in scaffolds, bio-inks, and engineered tissues enabling applications in wound healing, reconstructive surgery, and orthopedic repair.Ottawa, Feb. 10, 2026 (GLOBE NEWSWIRE) -- According
Zimmer Biomet Holdings Sees FY2026 Adj EPS $8.30-$8.45 vs $8.48 Est; Sees Sales $8.437B-$8.602B vs $8.612B Est
10.02.2026 07:32
Zimmer Biomet Holdings (NYSE:ZBH) is looking for FY2026 Adj EPS of $8.30-$8.45 vs $8.48 analyst estimate. sees sales of $8.437 billion-$8.602 billion vs $8.612 billion analyst estimate.
Zimmer Biomet Holdings Q4 Adj. EPS $2.42 Beats $2.40 Estimate, Sales $2.244B Beat $2.231B Estimate
10.02.2026 07:31
Zimmer Biomet Holdings (NYSE:ZBH) reported quarterly earnings of $2.42 per share which beat the analyst consensus estimate of $2.40 by 1 percent. This is a 4.76 percent increase over earnings of $2.31 per share from the
Earnings Preview: QuidelOrtho (QDEL) Q4 Earnings Expected to Decline
04.02.2026 15:00
QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) Valuation Check After Recent Share Price Weakness
04.02.2026 09:16
Why Zimmer Biomet Holdings (ZBH) Is On Investors’ Radar Today Zimmer Biomet Holdings (ZBH) is back in focus after recent share price moves, with the stock showing a negative 1 day return and mixed performance over the past week, month, and past 3 months. See our latest analysis for Zimmer Biomet Holdings. At a share price of $86.18, Zimmer Biomet’s 30 day share price return of a 4.27% decline sits against a 1 year total shareholder return of a 19.27% decline, suggesting momentum has softened...
3 Reasons ZBH is Risky and 1 Stock to Buy Instead
03.02.2026 04:03
Over the past six months, Zimmer Biomet’s shares (currently trading at $86.64) have posted a disappointing 6.2% loss, well below the S&P 500’s 9.6% gain. This might have investors contemplating their next move.
What Analysts Think Is Reframing Zimmer Biomet (ZBH) Story For Investors
27.01.2026 12:09
Zimmer Biomet Holdings is back in focus after a recent reset in its price target, putting fresh attention on how investors are framing the stock right now. With the new target reflecting updated expectations and risks, the story around the company is shifting in ways that matter for anyone tracking the shares. Stay tuned to see how you can keep on top of future changes in this narrative as they unfold. Analyst Price Targets don't always capture the full story. Head over to our Company Report...